Genix Pharmaceuticals Corporation (GENX.V)
| Previous Close | 0.0550 |
| Open | 0.0550 |
| Bid | 0.0600 x N/A |
| Ask | 0.0700 x N/A |
| Day's Range | 0.0550 - 0.0550 |
| 52 Week Range | 0.0200 - 0.0800 |
| Volume | |
| Avg. Volume | 16,379 |
| Market Cap | 3.257M |
| Beta (5Y Monthly) | -0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Genix Announces TSX-V Approval of Warrant Amendments
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that pursuant to its news release of January 18, 2024, the TSX Venture Exchange has approved the Company's application to amend both the exercise price and the warrant accelerator terms, in addition to extending the expiry dates of 3,354,945 previously issued and outstanding warrants (the "Warrants").The current exercise price of th
- Newsfile
Genix Announces Warrant Repricing and Seeks Extension
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend the exercise price, the warrant accelerator terms and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants").The Corporation is proposing to reduce the exercise price of the warrants from $0.30 per
- Newsfile
Genix Announces AGM Results
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") is pleased to report the results of the Annual General Meeting of shareholders held on May 18, 2023 (the "AGM"). Each of the director nominees proposed by management for election were elected to the Board of Directors: Sina Pirooz, Mahmoud Aziz, Kevin Bottomley, Jamie Lewin, and Paul Chow. In addition, the ...
